Frank V Fossella - JoVE Visualize

Showing results (31-40 of 62) with videos related to

Pageof 7

Sort By:

Cancer|July 20, 2005

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinomaEdward S Kim, Merrill S Kies, Frank V Fossella, et al.

Clinical Lung Cancer|April 28, 2006

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.

Lung Cancer (Amsterdam, Netherlands)|May 14, 2004

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final reportEdward S Kim, Joe B Putnam, Ritsuko Komaki, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, Jieling Miao, Ignacio I Wistuba, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011

Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinomaAnne S Tsao, Suyu Liu, Junya Fujimoto, et al.

The Annals of Thoracic Surgery|December 9, 2017

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung CancerTina Cascone, Kathryn A Gold, Stephen G Swisher, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.

Cancer|November 1, 2005

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancerRoy S Herbst, Timothy L Madden, Hai T Tran, et al.

Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:

Pageof 7

Cancer|July 20, 2005

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinomaEdward S Kim, Merrill S Kies, Frank V Fossella, et al.

Clinical Lung Cancer|April 28, 2006

Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.

Lung Cancer (Amsterdam, Netherlands)|May 14, 2004

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final reportEdward S Kim, Joe B Putnam, Ritsuko Komaki, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, Jieling Miao, Ignacio I Wistuba, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011

Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinomaAnne S Tsao, Suyu Liu, Junya Fujimoto, et al.

The Annals of Thoracic Surgery|December 9, 2017

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung CancerTina Cascone, Kathryn A Gold, Stephen G Swisher, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.

Cancer|November 1, 2005

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancerRoy S Herbst, Timothy L Madden, Hai T Tran, et al.

Pageof 7